News

Colleen DeSimone has more than 25 years of strategic financial and operational experience in the biotechnology and pharmaceutical industries. Most recently, she provided financial consulting services for Casma since its inception and for numerous early-stage biotechnology companies. Previously, Colleen served as vice president of finance and controller at Syros Pharmaceuticals. Colleen joined Syros from Takeda…

Andrea is thrilled to join Auron as chief people officer.   She has a demonstrated history of working in the biotechnology and healthcare industries, where she is skilled in biotech recruiting, professional development, executive coaching, strategic organizational development, planning and management.  She also serves as chief people officer at AI Proteins.  Andrea was the chief…

Tom Graeber, Ph.D. is the Chief Data Officer at Auron Therapeutics. Tom has an established academic career in the systems biology of cancer. His research integrates multi-omic profiling, experimentation, and computational biology. His work in integrated signaling and metabolic networks has repeatedly pointed to the importance of negative and positive feedback loops in cancer phenotypes,…

Before joining Auron, David was the Vice President of Chemistry at Foghorn Therapeutics, where he led and built the chemistry function, including a protein degrader platform. David played a key role in the early evolution of the company, through the IPO and contributed to bringing in partnerships with Merck and Lilly Loxo. He was a…

Kate Yen, PhD, is the Founder and CEO of Auron Therapeutics. Prior to founding Auron, she was a Director at Agios Pharmaceuticals, where she led the IDH translational research team that supported the preclinical and clinical development and approval of two IDH mutant inhibitors, IDHIFA®  and TIBSOVO. She led the proof of concept studies that…